Vertex Stops Test of Rare Disease Drug, Dimming Pipeline Prospects

VERTEX STOPS TEST OF RARE DISEASE DRUG, DIMMING PIPELINE PROSPECTS

Vertex Pharmaceuticals is halting work on an experimental drug for a rare protein deficiency after safety problems were reported in...

Sanofi, Pfizer & Bristol Drugs Among the 12 Approvals to Look Out for in Q4

SANOFI, PFIZER & BRISTOL DRUGS AMONG THE 12 APPROVALS TO LOOK OUT FOR IN Q4

The end of the year should see a flurry of new products reaching the market to break new commercial ground or shake up their respective...

 
 
 
Roche Enlists Dyno to Bring AI to Next-Generation Liver, CNS Gene Therapies

ROCHE ENLISTS DYNO TO BRING AI TO NEXT-GENERATION LIVER, CNS GENE THERAPIES

Roche made a splash with its acquisition of Spark Therapeutics, whose Luxturna, a gene therapy for an inherited form of vision loss,...

Codiak Bio's IPO Brings In $82M as Exosome Clinical Trials Begin

CODIAK BIO'S IPO BRINGS IN $82M AS EXOSOME CLINICAL TRIALS BEGIN

Codiak BioSciences now has $82.5 million to fund clinical tests of a new class of medicines based on exosomes, tiny bubbles formed...

 
 
 
Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma

DESPITE PHASE 2 FAILURE, GOSSAMER BIO SEES A PATH FOR DRUG IN ASTHMA

Gossamer Bio's lead drug, an experimental treatment for asthma and allergies, has failed in two mid-stage clinical trials but the biotech...

SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D

SQZ BIOTECH LINES UP AN IPO ON THE NYSE TO FUND CELL THERAPY R&D

SQZ Biotechnologies, which already has an alliance with Roche focused on developing new cancer cell therapies, is now looking to sell...

 
 
 
“Opioid Stacking” Concerns Lead FDA to Reject Avenue Therapeutics Drug

“OPIOID STACKING” CONCERNS LEAD FDA TO REJECT AVENUE THERAPEUTICS DRUG

An opioid that Avenue Therapeutics reformulated for treating post-surgical pain in hospital settings has been rejected by the FDA due...

 
 
 
Bio Roundup: CRISPR Kudos, Bristol Myers's Buy, RNAi Alliance & More

BIO ROUNDUP: CRISPR KUDOS, BRISTOL MYERS'S BUY, RNAI ALLIANCE & MORE

It's October: a time of days growing shorter, leaves changing color, and phone calls in the wee hours that rouse scientists from slumber...

Biogen's AdComm Meeting Will Test FDA's “Substantial Evidence” Flexibility

BIOGEN'S ADCOMM MEETING WILL TEST FDA'S “SUBSTANTIAL EVIDENCE” FLEXIBILITY

A US Food and Drug Administration advisory committee meeting on Biogen, Inc.'s Alzheimer's drug aducanumab will offer some insight...

 
 
 
 
 
 
 
 
 
Genfit Restructuring Cuts Staff by 40%, Creates Two New Subsidiaries

GENFIT RESTRUCTURING CUTS STAFF BY 40%, CREATES TWO NEW SUBSIDIARIES

Genfit is halting all work on its lead drug in the fatty liver disorder nonalcoholic steatohepatitis and implementing a corporate restructuring...

Bristol Myers to Buy MyoKardia, FDA-Ready Heart Disease Drug for $13.1B

BRISTOL MYERS TO BUY MYOKARDIA, FDA-READY HEART DISEASE DRUG FOR $13.1B

Bristol Myers Squibb is bolstering its cardiovascular drug lineup with a $13.1 billion deal to acquire MyoKardia, a company whose experimental...

 
 
 
Bristol Myers's Hirawat on Pipeline Progress, Clinical Trial Diversity

BRISTOL MYERS'S HIRAWAT ON PIPELINE PROGRESS, CLINICAL TRIAL DIVERSITY

As the one-year anniversary of Bristol-Myers Squibb Company's $74bn acquisition of Celgene Corporation approaches, Scrip spoke with...

Bio Roundup: MESO's Miss, Pfizer's Cancer Bet, Vaccine Promise & More

BIO ROUNDUP: MESO'S MISS, PFIZER'S CANCER BET, VACCINE PROMISE & MORE

Amid the bombast of Tuesday's presidential debate, viewers caught some discussion about the response to the coronavirus pandemic and...

 
 
 
FDA Lifts Solid Bio Clinical Hold, Duchenne Study Cleared to Resume

FDA LIFTS SOLID BIO CLINICAL HOLD, DUCHENNE STUDY CLEARED TO RESUME

Solid Biosciences has answered the FDA's outstanding questions about its Duchenne muscular gene therapy, clearing a clinical trial...

Genfit Restructuring Cuts Staff by 40%, Creates Two New Subsidiaries

GENFIT RESTRUCTURING CUTS STAFF BY 40%, CREATES TWO NEW SUBSIDIARIES

Genfit is halting all work on its lead drug in the fatty liver disorder nonalcoholic steatohepatitis and implementing a corporate restructuring...

 
 
 



World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Mail Online: Vaccine roll out issues

Mail Online: Vaccine roll out issues

GreenLight Biosciences explain to the Mail Online about the vaccine roll out issues for a Covid-19 vaccine. GreenLight Biosciences spoke to Mail Online about the vaccine supply... Read more ...

Primer on Carbon Dioxide Removal Provides Vital Resource at Critical Time

Primer on Carbon Dioxide Removal Provides Vital Resource at Critical Time

Berkeley Lab researchers are working on ways to sequester more carbon in soil, including through agricultural practices. Scientists say that any serious plan to address... Read more ...

A 1-Atom-Deep Look at a Water-Splitting Catalyst

A 1-Atom-Deep Look at a Water-Splitting Catalyst

This illustration shows two possible types of surface layers for a catalyst that performs the water-splitting reaction, the first step in making hydrogen fuel: The gray surface... Read more ...

New Research Technique Sheds Light on Least Understood Part of Lithium Batteries

New Research Technique Sheds Light on Least Understood Part of Lithium Batteries

A scientist works on the MALDI (matrix-assisted laser desorption/ionization) mass spectrometer at Berkeley Lab's Molecular Foundry. One of the aspects of lithium-ion batteries... Read more ...

Ozone Generators May Help Remediate Contamination Caused by Thirdhand Smoke

Ozone Generators May Help Remediate Contamination Caused by Thirdhand Smoke

Residue from cigarettes can linger on indoor surfaces for years and even decades. In 10 years of studying thirdhand smoke, which is the toxic cigarette residue that clings to... Read more ...

Financial Times: Get vaccine new variant ready

Financial Times: Get vaccine new variant ready

GreenLight Biosciences explain to the Financial Times how messenger RNA can help get the Covid-19 vaccine new variant ready. GreenLight Biosciences spoke to the Financial Times... Read more ...

Shine On: Avalanching Nanoparticles Break Barriers to Imaging Cells in Real Time

Shine On: Avalanching Nanoparticles Break Barriers to Imaging Cells in Real Time

From left: Experimental images of thulium-doped avalanching nanoparticles separated by 300 nanometers; at right, simulations of the same material. (Credit: Berkeley Lab and... Read more ...

NextCure hires Celgene vet as CMO; José Vega leaves Merck to become...

NextCure has found its new CMO after the previous executive resigned last August. Han Myint, a biopharma and academia veteran of more than 20 years, joined the company Thursday... Read more ...

Prometheus Biosciences: Director, Clinical Operations

Prometheus Biosciences: Director, Clinical Operations Company Description Pre-IPO, clinical stage biotech with lead asset in Ph 1 and potential for first-in-class mechani San... Read more ...

In LA, ambulances circle for hours and ICUs are full. Is this what Covid-19...

Do the overwhelmed hospitals in Los Angeles offer a glimpse of what other regions may soon face as case counts rise steeply and a seemingly more infectious strain takes hold?... Read more ...